checkAd

     265  0 Kommentare Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences

    NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in two upcoming investor conferences:

    2024 RBC Capital Markets Global Healthcare Conference
    Tuesday, May 14, 2024 at 10:00 a.m. ET in New York, NY

    Bank of America Healthcare Conference 2024
    Thursday, May 16, 2024 at 9:20 a.m. PT (12:20 p.m. ET) in Las Vegas, NV

    A live and archived webcast of the presentations can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

    About Intra-Cellular Therapies

    Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.

    Contact:

    Intra-Cellular Therapies, Inc.
    Juan Sanchez, M.D.
    Vice President, Corporate Communications and Investor Relations
    646-440-9333

    Burns McClellan, Inc.
    Cameron Radinovic / Lee Roth
    cradinovic@burnsmc.com / lroth@burnsmc.com
    646-930-4406





    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) - Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that …